- Home
- SGML vs ABUS Comparison
SGML vs ABUS Comparison
Compare SGML & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- ABUS
- Stock Information
- Founded
- SGML 2011
- ABUS 2005
- Country
- SGML Brazil
- ABUS United States
- Employees
- SGML N/A
- ABUS N/A
- Industry
- SGML Industrial Machinery/Components
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- ABUS Health Care
- Exchange
- SGML Nasdaq
- ABUS Nasdaq
- Market Cap
- SGML 743.4M
- ABUS 711.2M
- IPO Year
- SGML N/A
- ABUS N/A
- Fundamental
- Price
- SGML $5.41
- ABUS $4.46
- Analyst Decision
- SGML Strong Buy
- ABUS Strong Buy
- Analyst Count
- SGML 1
- ABUS 2
- Target Price
- SGML $16.00
- ABUS $5.00
- AVG Volume (30 Days)
- SGML 2.8M
- ABUS 1.6M
- Earning Date
- SGML 08-15-2025
- ABUS 11-05-2025
- Dividend Yield
- SGML N/A
- ABUS N/A
- EPS Growth
- SGML N/A
- ABUS N/A
- EPS
- SGML N/A
- ABUS N/A
- Revenue
- SGML $134,494,014.00
- ABUS $15,416,000.00
- Revenue This Year
- SGML $26.70
- ABUS $138.02
- Revenue Next Year
- SGML $42.31
- ABUS N/A
- P/E Ratio
- SGML N/A
- ABUS N/A
- Revenue Growth
- SGML N/A
- ABUS 53.23
- 52 Week Low
- SGML $4.25
- ABUS $2.71
- 52 Week High
- SGML $15.56
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- SGML 41.48
- ABUS 66.80
- Support Level
- SGML $5.35
- ABUS $4.01
- Resistance Level
- SGML $6.63
- ABUS $5.10
- Average True Range (ATR)
- SGML 0.38
- ABUS 0.25
- MACD
- SGML -0.11
- ABUS 0.09
- Stochastic Oscillator
- SGML 3.78
- ABUS 60.25
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.